Hela Radiopharma AB

Developing Sweden's first privately owned, industrial-scale radiopharmaceutical production hub.

Website: https://www.helaradiopharma.com/

Cover Block

From the public record

Field Value
Name Hela Radiopharma AB
Tagline Developing Sweden's first privately owned, industrial-scale radiopharmaceutical production hub.
Headquarters Stockholm, Sweden
Founded 2024
Stage Pre-Seed
Business Model B2B
Industry Healthtech
Technology Biotech / Life Sciences
Geography Western Europe
Growth Profile Venture Scale
Founding Team Co-Founders (2)
Funding Label Pre-seed

Links

From the public record

The Short Version

PUBLIC Hela Radiopharma AB is developing a planned radiopharmaceutical production hub in Sweden, a proposition that merits attention because the company is targeting PET and theranostic isotope supply with an explicitly industrial manufacturing thesis rather than a software abstraction layered on top of healthcare workflows [Hela Radiopharma, January 2026]. Founded in 2024 and based in the Stockholm area, the company presents itself as Sweden's first privately owned, industrial-scale radiopharmaceutical production hub, although that positioning rests on company statements rather than independent sector reporting [LinkedIn, current company profile] [Hela Radiopharma, January 2026].

The core service is intended isotope production for research, clinical trials, and commercial pharmaceutical use, with planned use of Sumitomo Heavy Industries' HM-20 and MP-30X cyclotrons; the differentiation, as publicly framed, is local capacity in Sweden and Northern Europe for a supply chain that is often constrained by specialized infrastructure and time-sensitive logistics [Hela Radiopharma, January 2026] [Report Prime]. The company's website also frames the facility as a future GMP-certified CMO/CDMO asset and as a Northern European hub for theranostics and targeted alpha therapy, but there is no public evidence yet of an operating facility, regulatory approval, named customers, or signed supply agreements [Hela Radiopharma, January 2026].

On team, the public record is narrow but relevant. Liliane Rothoff is identified on LinkedIn as co-founder and managing director, with the managing director role beginning in January 2025, and her profile describes experience across radiopharmaceutical production, medical technology, and advanced production environments; a separate company page shows she also serves as Commercial Product Manager at Lioness MedTech [LinkedIn, current profile for Liliane Rothoff] [Lioness MedTech].

The capital structure visible in public is still minimal. No confirmed venture round or institutional backer appears in the available sources, while Bolagsfakta reports two employees and a Swedish company information listing cited in the research reports SEK 25,000 in registered share capital and 25,000 registered shares, figures that indicate legal incorporation rather than operating scale or external financing [Bolagsfakta.se, retrieved 2026].

From an investor's standpoint, this is an infrastructure-first B2B biotech bet with an early public footprint and a long list of execution gates still ahead. Over the next 12 to 18 months, the signals that matter are straightforward: evidence of facility build-out in Stockholm, procurement and installation progress for the planned cyclotrons, regulatory and GMP readiness, and the first externally verifiable customer or partnership announcements [Hela Radiopharma, January 2026] [LinkedIn, current company profile].

Unconfirmed -- This section relies materially on company website statements and self-reported LinkedIn profiles, with limited independent corroboration from Bolagsfakta.

Taxonomy Snapshot

Axis Value
Stage Pre-Seed
Business Model B2B
Industry / Vertical Healthtech
Technology Type Biotech / Life Sciences
Geography Western Europe
Growth Profile Venture Scale
Founding Team Co-Founders (2)
Funding Pre-seed

The Company in Brief

PUBLIC

Hela Radiopharma AB enters the record with a narrow but intelligible public footprint: a Swedish company formed in 2024, based in the Stockholm area, and presenting itself as a developer of radiopharmaceutical manufacturing infrastructure rather than a drug developer in the usual venture sense [Hela Radiopharma, January 2026]. The company describes its core project as Sweden's first privately owned, industrial-scale radiopharmaceutical production hub, aimed at PET and theranostic radioisotopes, with a facility planned in Stockholm/Sweden [Hela Radiopharma, January 2026].

The chronology that can be supported from public filings is still early. Bolagsfakta identifies Hela Radiopharma Sweden AB as a Swedish aktiebolag and lists registration details consistent with an August 21, 2024 company formation, alongside registered share capital of SEK 25,000 and 25,000 registered shares [Bolagsfakta.se, retrieved 2026]. By January 2026, the company's website had added a more specific operating ambition: production for research, clinical trials, and commercial pharmaceutical use, supported by planned Sumitomo Heavy Industries HM-20 and MP-30X cyclotrons [Hela Radiopharma, January 2026]. That sequence matters because it frames Hela, at least publicly, as a newly incorporated infrastructure build rather than an already operating isotope supplier [Bolagsfakta.se, retrieved 2026] [Hela Radiopharma, January 2026].

Public leadership detail is limited but directionally relevant. The available company materials do not present a full leadership roster, though Liliane Rothoff publicly identifies herself as co-founder and managing director, with that managing director role beginning in January 2025 according to her LinkedIn profile [LinkedIn, current profile for Liliane Rothoff]. Within the boundaries of public evidence, the company appears to be at formation-stage institution building: legal entity established, operating thesis articulated, and production infrastructure specified, with later execution milestones still to be demonstrated in public sources [Bolagsfakta.se, retrieved 2026] [Hela Radiopharma, January 2026].

Single-source, plausible -- Confirmed in part by Hela Radiopharma's website and Bolagsfakta.se; several operating claims remain company-stated rather than independently corroborated.

What They Have Built

Mixed sourcing

The product story is still mostly a facilities and supply thesis, not a software surface or commercialized platform. Hela Radiopharma says it is developing Sweden’s first privately owned, industrial-scale radiopharmaceutical production hub, with an initial focus on PET and theranostic radioisotopes, and it frames the planned site as production infrastructure for research, clinical trials, and commercial pharmaceutical use [Hela Radiopharma, January 2026]. In plain terms, the company is proposing to manufacture and supply medically relevant isotopes rather than sell a finished therapeutic product of its own, a distinction that matters because the technical burden sits in cyclotron operation, production quality, and regulated facility buildout [Hela Radiopharma, January 2026].

The public technical detail that can be verified is narrow but specific. Hela states that the planned production setup will use Sumitomo Heavy Industries’ HM-20 and MP-30X cyclotrons [Hela Radiopharma, January 2026], and third-party market material indicates Sumitomo supplies cyclotrons for medical and industrial isotope applications [Report Prime]. The same company page describes GMP-certified CMO/CDMO infrastructure and positions the facility as a Northern European hub for theranostics and targeted alpha therapy, although those claims remain company-described intent rather than evidence of an operating plant, validated output, or commercial supply agreements [Hela Radiopharma, January 2026].

What is absent from the public record is as informative as what is present. There is no verified public evidence here of an operational launch, regulatory approval, named customer deployment, production batch history, or a demonstrated manufacturing workflow beyond the company’s own description of the planned facility and equipment base [Hela Radiopharma, January 2026]. That keeps the technical assessment conservative for now: the concept is legible, the equipment choice is specific, but execution risk remains concentrated in facility commissioning and proof that the proposed manufacturing stack can move from announced design to dependable isotope supply.

Unconfirmed -- This section relies primarily on company website claims, with limited external corroboration from a third-party description of Sumitomo cyclotron applications [Hela Radiopharma, January 2026; Report Prime].

Market Size and Demand

PUBLIC

The market matters because radiopharmaceutical supply remains constrained by short isotope half-lives and specialized production requirements, so any new manufacturing node sits at the intersection of oncology demand, industrial bottlenecks, and regulated infrastructure buildout [Hela Radiopharma, January 2026].

Public evidence on Hela Radiopharma's addressable market is thin, and there is no named third-party TAM, SAM, or SOM figure in the provided source set for the company itself. That limits precision. What can be said from public materials is narrower and still useful: Hela is positioning into the supply layer for PET and theranostic radioisotopes, with stated end markets spanning research, clinical trials, and commercial pharmaceutical use [Hela Radiopharma, January 2026].

That framing implies an addressable demand pool that is broader than a single customer type. It reaches pharmaceutical companies running development programs, trial sponsors needing reliable isotope access, research organizations, and healthcare providers dependent on timely supply [Hela Radiopharma, January 2026]. The commercial logic is plausible because isotope distribution is unusually sensitive to geography and uptime, but that remains an inference from the production model rather than a verified demand signal such as contracts or announced customer programs [Hela Radiopharma, January 2026].

The public demand drivers are easier to identify than the market size. Hela's own materials tie the buildout to precision oncology, theranostics, and targeted alpha therapy, and present local manufacturing as a response to shortages and supply chain dependence in Northern Europe [Hela Radiopharma, January 2026]. Those claims are company-sourced, so they should be read as strategic intent rather than independently verified market proof, but they are directionally consistent with why radiopharmaceutical infrastructure attracts interest: supply reliability can be as important as molecule innovation when products have narrow logistics windows.

A second tailwind sits in the production stack Hela says it wants to assemble. The company plans to use Sumitomo Heavy Industries' HM-20 and MP-30X cyclotrons, and third-party industry commentary describes Sumitomo as a supplier serving medical and industrial isotope applications [Hela Radiopharma, January 2026] [Report Prime]. That does not validate Hela's execution, but it does indicate the company is orienting around equipment designed for the category it wants to serve, which matters in a market where manufacturing capability, not just scientific ambition, shapes who can participate.

Adjacent markets are visible even without formal sizing data. PET imaging radioisotopes sit closer to diagnostic medicine and research workflows, while theranostic and targeted alpha therapy supply reaches further into oncology treatment pathways and commercial pharma manufacturing [Hela Radiopharma, January 2026]. The practical substitute for a domestic production hub is continued dependence on imported isotope supply or external contract manufacturing, which is precisely the dependency Hela says it aims to reduce in Sweden and the broader Northern European corridor [Hela Radiopharma, January 2026].

Regulation is the constraint that turns this from a straightforward equipment purchase into a harder infrastructure market. Hela's website refers to GMP-certified CMO/CDMO infrastructure and commercial pharmaceutical use, both of which imply a need for quality systems and regulatory readiness before any meaningful revenue ramp could occur [Hela Radiopharma, January 2026]. Public sources provided here do not verify an operational launch, production batches, or regulatory approvals, so the market opportunity should be viewed as accessible only after those milestones are met [Hela Radiopharma, January 2026].

Market lens Public support Read-through
Core demand area PET and theranostic radioisotopes [Hela Radiopharma, January 2026] Indicates exposure to both diagnostic and therapeutic radiopharma workflows
Buyer set Pharma companies, clinical-trial sponsors, research organizations, healthcare providers [Hela Radiopharma, January 2026] Suggests a multi-segment B2B market if supply can be qualified
Supply-side tailwind Claimed need to address shortages and supply-chain dependence [Hela Radiopharma, January 2026] Points to infrastructure scarcity as part of the wedge, though not independently verified
Enabling equipment HM-20 and MP-30X cyclotrons; Sumitomo serves medical and industrial isotope applications [Hela Radiopharma, January 2026] [Report Prime] Supports category fit at the equipment level, not facility completion

The table shows a market defined less by a single published TAM figure than by where supply constraints, oncology demand, and regulated production overlap. For investors, that usually means the market can be strategically attractive before it is easy to measure, but only if later diligence confirms approvals, commissioning progress, and customer qualification.

Unconfirmed -- This section relies primarily on company website claims, with limited third-party support from Report Prime and no independent market-sizing report in the provided sources.

Who Else Is Fighting for This

Competitive dynamics

MIXED Hela Radiopharma is not competing first on drug discovery or hospital delivery, but on whether a new Swedish production site can become a credible local manufacturing alternative for PET and theranostic isotope supply in a market that still appears to rely heavily on established infrastructure providers and equipment vendors [Hela Radiopharma, January 2026].

The competitive map is narrow in public evidence, and that matters. No named direct competitor appears in the source set, so the clearest public comparison is by segment rather than by company: incumbent isotope producers and radiopharma manufacturers on one side, cyclotron and equipment suppliers on another, and adjacent substitutes such as imported isotope supply chains or hospital-linked production capacity in the background [Hela Radiopharma, January 2026] [Report Prime]. Hela's own language places it in the manufacturing and supply layer, aimed at research, clinical-trial, and commercial pharmaceutical customers, rather than in the therapeutic developer layer [Hela Radiopharma, January 2026].

On the evidence available, Hela's edge today is mostly positional and still largely aspirational. The company is trying to establish a domestic or regional foothold around local production in Sweden, with planned use of Sumitomo Heavy Industries HM-20 and MP-30X cyclotrons, and it frames that positioning around supply-chain dependence and shortages in radiopharmaceutical inputs [Hela Radiopharma, January 2026]. That could matter if local manufacturing reduces lead times or improves reliability for time-sensitive isotopes, but the durability of that edge is perishable until the facility is built, qualified, and shown to operate at commercial standards. Publicly, there is not yet evidence of regulatory approvals, named customers, signed supply agreements, or production output that would convert stated intent into a hard competitive moat [Hela Radiopharma, January 2026].

The company appears most exposed to established operators that already have operating assets, customer relationships, and compliance history, even if those operators are not named in the current source base. Hela does not own the equipment layer, since Sumitomo is the cited cyclotron supplier rather than an in-house technology stack [Hela Radiopharma, January 2026] [Report Prime]. It also does not yet appear to own a distribution channel or customer base in public, which leaves execution risk concentrated in facility delivery, qualification, and early account capture. The current public footprint is thin, with a LinkedIn headcount band of 1 to 10 and a company listing showing two employees, which is consistent with a very early operating posture rather than an already scaled supply platform [LinkedIn, current company profile] [Bolagsfakta.se].

The most plausible 18-month scenario is that the competitive field is sorted less by branding than by who converts plans into operating capacity first. Sumitomo Heavy Industries is the clearest named winner if demand for new cyclotron-based capacity rises across Northern Europe, because it sells into the infrastructure build-out regardless of which producer ultimately gains share [Report Prime] [Hela Radiopharma, January 2026]. Hela is the clearest named loser if facility development, customer qualification, or commercialization slips, since its present positioning depends on infrastructure that the public record does not yet show as completed or in production [Hela Radiopharma, January 2026] [LinkedIn, current company profile].

Unconfirmed -- This section relies primarily on company statements about intended positioning and product scope, with limited corroboration from LinkedIn, Bolagsfakta.se, and a third-party description of Sumitomo's cyclotron applications.

Opportunity

Upside case

PUBLIC The prize here is straightforward: if Hela Radiopharma executes on its current plan, it could become a key regional manufacturing node for PET and theranostic radioisotopes in Sweden and, over time, a broader Northern European supply chain layer for radiopharmaceutical development and commercial supply [Hela Radiopharma, January 2026].

The headline opportunity rests less on novel drug discovery and more on infrastructure control. Hela says it is building Sweden's first privately owned, industrial-scale radiopharmaceutical production hub, with planned use of Sumitomo Heavy Industries HM-20 and MP-30X cyclotrons and a stated focus on research, clinical trials, and commercial pharmaceutical use [Hela Radiopharma, January 2026]. If that facility is built, qualified, and brought into regulated production, the company would sit at an attractive junction in the value chain: upstream of hospitals and trial sites that need isotope supply, and adjacent to pharmaceutical companies and research organizations that need manufacturing capacity without building it themselves [Hela Radiopharma, January 2026]. That is a reachable outcome only in a narrow sense today, because the available evidence confirms the intent, location focus, and equipment plan, but not yet an operating plant, customer base, or approvals [Hela Radiopharma, January 2026] [LinkedIn, current company profile].

A compact way to frame the upside is through scenario paths rather than a single outcome. The common thread across all of them is that industrial isotope production tends to reward capacity, reliability, and geographic proximity once a site is qualified, even if the public record here is still early.

Scenario What happens Catalyst Why it's plausible
Swedish anchor supplier Hela becomes a domestic contract manufacturing and supply partner for Swedish research groups, clinical-trial sponsors, and healthcare providers needing PET and therapeutic isotopes Completion of the planned Stockholm-area facility and deployment of the HM-20 and MP-30X cyclotrons [Hela Radiopharma, January 2026] The company is explicitly positioning around local industrial-scale production in Sweden, with intended supply across research, trials, and commercial use [Hela Radiopharma, January 2026]
Northern Europe theranostics hub Hela expands from national supply into cross-border regional infrastructure for theranostics and targeted alpha therapy programs A first wave of regional customer qualification and GMP manufacturing utilization after site launch [Hela Radiopharma, January 2026] Hela's own positioning is as a "Northern European Hub for Theranostics and Targeted Alpha Therapy," and the planned infrastructure is framed for more than one end market [Hela Radiopharma, January 2026]
Platform manufacturing partner Hela becomes a specialist CMO/CDMO-style isotope production partner for pharmaceutical developers that prefer outsourced production over internal buildout Securing repeat production mandates tied to clinical development programs and eventual commercial demand [Hela Radiopharma, January 2026] The company states an intent to serve pharmaceutical companies and clinical-trial sponsors, and to support commercial pharmaceutical use rather than research alone [Hela Radiopharma, January 2026]

The compounding mechanism, if it appears, would likely come from regulated capacity rather than classic software network effects. One validated site can support multiple customer types, and each successful production relationship can make the next one easier by proving quality systems, delivery reliability, and equipment utilization. Hela's website already frames the business around GMP-certified CMO/CDMO infrastructure and industrial-scale production, which suggests management understands that trust and qualification are part of the product, not only isotope output [Hela Radiopharma, January 2026]. Still, the public record does not yet show that this flywheel has started. LinkedIn and Bolagsfakta indicate a company that remains very small, at 1 to 10 employees on LinkedIn and 2 employees on Bolagsfakta, which is consistent with a pre-build phase rather than an operating manufacturing engine [LinkedIn, current company profile] [Bolagsfakta.se].

The size of the win is best described qualitatively because the source set here does not provide a credible public market size, peer valuation, or transaction comparable specific enough to support a hard valuation range. In a successful version of the "Northern Europe theranostics hub" scenario, the business could become strategically important infrastructure for a supply-constrained part of precision medicine, with value driven by scarce production capacity, regulatory qualification, and embedded customer relationships rather than by broad brand reach (scenario, not a forecast) [Hela Radiopharma, January 2026]. Investors should read that upside as real but still conditional: the company has articulated a valuable place in the stack, yet the public evidence today confirms ambition and positioning more clearly than execution milestones.

Unconfirmed -- This section relies primarily on company website claims about planned facilities, positioning, and intended customers, with limited corroboration from LinkedIn and Bolagsfakta on company size and existence.

Sources

From the public record

  1. [Hela Radiopharma, January 2026] Home | https://www.helaradiopharma.com/

  2. [LinkedIn, current company profile] Hela Radiopharma Sweden AB | https://www.linkedin.com/company/hela-radiopharma-ab

  3. [Report Prime] Top 10 Laboratory Cyclotrons Companies | Report Prime | https://www.reportprime.com/laboratory-cyclotrons-r8900/company

  4. [LinkedIn, current profile for Liliane Rothoff] Liliane Rothoff | https://www.linkedin.com/in/liliane-rothoff

  5. [Lioness MedTech] CONTACT - Lioness MedTech | https://lionessmedtech.com/contact/

  6. [Bolagsfakta.se, retrieved 2026] Hela Radiopharma Sweden AB | Aktiebolag | Info & Löner | https://www.bolagsfakta.se/5594936402-Hela_Radiopharma_Sweden_AB

Articles about Hela Radiopharma AB

View on Startuply.vc